Global Drug Eluting Balloons Market Size Study, by Product (Coronary Drug Eluting Balloon, Peripheral Drug Eluting Balloon, Others), by Technology (Paccocath, FreePac, TransPax, EnduraCoat, Others), by End-user (Hospitals and Ambulatory Surgery Centers, C

Global Drug Eluting Balloons Market Size Study, by Product (Coronary Drug Eluting Balloon, Peripheral Drug Eluting Balloon, Others), by Technology (Paccocath, FreePac, TransPax, EnduraCoat, Others), by End-user (Hospitals and Ambulatory Surgery Centers, Cath Labs, Others) and Regional Forecasts 2024-2032

The Global Drug Eluting Balloons Market is valued approximately at USD 615.23 Million in 2023 and is anticipated to grow with a healthy growth rate of more than 7.72% over the forecast period 2024-2032. Drug-eluting balloons (DEBs) are medical devices used in the treatment of vascular diseases, particularly in the context of angioplasty for peripheral and coronary artery disease. They combine the functions of a balloon catheter with drug delivery to improve outcomes in angioplasty procedures. The market is being driven by the increasing prevalence of coronary artery disease and diabetes, which are leading causes of the rising demand for advanced therapeutic interventions. Drug-eluting balloons are pivotal in the treatment of coronary artery disease, offering a less invasive option compared to traditional stents and surgeries.

The increasing incidence of cardiovascular diseases globally is a significant driver for market growth. According to the World Health Organization (WHO), coronary heart disease is a leading cause of death worldwide, claiming millions of lives annually. This high prevalence is expected to drive the demand for angioplasty and other related treatments, consequently boosting the drug-eluting balloons market. In addition, the rising prevalence of diabetes, which can lead to cardiovascular complications, is further propelling market growth. Diabetes is a significant health concern globally, with the WHO reporting millions of deaths attributed to the disease each year. For instance, the Centers for Disease Control and Prevention (CDC) reported that in 2021, approximately 537 million adults worldwide had diabetes, with numbers expected to rise. Such statistics underscore the growing need for effective cardiovascular treatments, including drug-eluting balloons, thus fostering market growth.

The Key regions considered for the global Drug Eluting Balloons market study include North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America held the dominant market share in 2023, attributed to the presence of leading manufacturers, the introduction of technologically advanced devices, and favorable reimbursement policies. The region's advanced healthcare infrastructure, high adoption rates of innovative medical technologies, and substantial investments in research and development contribute significantly to its leadership position. North America's well-established medical device industry and the presence of major healthcare companies enhance the availability and use of DEBs. Additionally, the growing prevalence of cardiovascular diseases and peripheral artery disease in the region increases the demand for effective treatment options, such as DEBs. The region's regulatory environment and supportive reimbursement policies further facilitate market growth, making North America a key player in the global DEBs market. Europe also holds a significant market share due to the high prevalence of cardiovascular diseases. Meanwhile, the Asia-Pacific region is expected to witness the fastest growth, driven by rising healthcare expenditures and increasing cases of cardiovascular diseases.

Major market players included in this report are:

Bayer AG

Medtronic

B. Braun Melsungen AG

Cook Medical, Inc.

Boston Scientific Corporation

Becton, Dickinson and Company

EuroCor

Terumo Corporation

Koninklijke Philips N.V.

SurModics Inc.

The detailed segments and sub-segments of the market are explained below:

By Product:

Coronary Drug Eluting Balloon

Peripheral Drug Eluting Balloon

Others

By Technology:

Paccocath

FreePac

TransPax

EnduraCoat

Others

By End-user:

Hospitals and Ambulatory Surgery Centers

Cath Labs

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.